Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01898013 · ClinicalTrials.gov registry record · Phase 2

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

A Phase 2 study, sponsored by Durham VA Medical Center.

Completed
Registry status
Phase 2
Development phase
94
Enrollment target

NCT01898013 is a Phase 2 study that has completed, run by Durham VA Medical Center. The registered enrollment target is 94 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01898013, a Phase 2 study, has completed, sponsored by Durham VA Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
94 participants
Enrollment target

Study Summary

The study design is a randomized, double-blind, two-arm trial of pregnenolone and placebo to determine the possible analgesic effects in OEF/OIF Veterans with chronic low back pain. The total study duration is 6 weeks (followed by two-follow up phone calls). All patients will monitor pain symptoms for one week with pain diaries, followed by a 1-week placebo-only lead-in period, 90 subjects will be randomly assigned to one of two groups. Of these subjects, 45 subjects will receive pregnenolone, and 45 subjects will receive placebo for 4 weeks. Patient interview assessments and laboratory studies will be performed at each interview time point. Pregnenolone, allopregnanolone and other neurosteroid metabolites will be determined by gas chromatography / mass spectrometry (GC/MS), proceeded by high performance liquid chromatography (HPLC).

Interventions

  • DRUG Placebo
  • DRUG Pregnenolone

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2013-09-13
Est. Completion 2017-04-03
Phase Phase 2

Sponsor

Durham VA Medical Center

17 total trials

What the Registry Record Tells You About NCT01898013

The ClinicalTrials.gov registry entry for NCT01898013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durham VA Medical Center, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01898013 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01898013 about?

NCT01898013 is a clinical study titled "Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans". The study design is a randomized, double-blind, two-arm trial of pregnenolone and placebo to determine the possible analgesic effects in OEF/OIF Veterans with chronic low back pain. The total study duration is 6 weeks (followed by two-follow up phone calls). All patients will monitor pain symptoms f...

What is the current status of trial NCT01898013?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2013-09-13. Estimated completion is 2017-04-03.

What interventions are being tested in trial NCT01898013?

The interventions under investigation include: Placebo (DRUG), Pregnenolone (DRUG).

Who is sponsoring clinical trial NCT01898013?

This trial is sponsored by Durham VA Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.